You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 9,370,483


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,370,483
Title:Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
Inventor(s): Dhuppad; Ulhas R. (Maharashtra, IN), Katkurwar; Ashok (Maharashtra, IN), Gupta; Yashwant (Maharashtra, IN), Ankam; Rajesh (Maharashtra, IN), Dhatrak; Chandrakant (Maharashtra, IN)
Assignee: GLENMARK SPECIALTY S.A. (La Chaux-de-Fonds, CH)
Application Number:14/662,128
Patent Claim Types:
see list of patent claims
Composition;
Patent landscape, scope, and claims:

United States Patent 9,370,483: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 9,370,483 is a significant patent that has garnered attention in the intellectual property landscape. This article provides a comprehensive analysis of the patent's scope, claims, and the broader patent landscape in which it resides.

Patent Overview

Patent Number and Title

The patent in question is U.S. Patent 9,370,483. While the specific title of the patent is not provided in the sources, it is crucial to identify the title and the general subject matter to understand its scope and claims.

Inventors and Assignees

Identifying the inventors and assignees is essential for understanding the ownership and potential licensing or litigation issues associated with the patent. This information can be found through the USPTO's patent search tools[4].

Scope of the Patent

Claim Language and Scope

The scope of a patent is largely defined by its claims. Independent claim length and count are simple yet effective metrics for measuring patent scope. Research indicates that narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Claim Types

The patent includes various types of claims, such as independent and dependent claims. Independent claims define the broadest scope of the invention, while dependent claims narrow down the scope by adding additional limitations.

Claims Analysis

Independent Claims

Independent claims are critical as they set the broadest boundaries of what is patented. For U.S. Patent 9,370,483, analyzing these claims involves identifying the key elements and limitations that define the invention.

Dependent Claims

Dependent claims build upon the independent claims by adding specific details or limitations. These claims help to further define the invention and can provide additional protection against infringement.

Patent Landscape

Related Patents and Family Members

Understanding the patent family, including continuations, continuations-in-part, and divisional applications, is vital. This can be done using tools like the USPTO's Global Dossier or the Patent Public Search tool[4].

Prior Art and Citations

Analyzing prior art and citations can provide insights into the novelty and non-obviousness of the patented invention. Tools like the Common Citation Document (CCD) help consolidate prior art cited by multiple patent offices[4].

Expiration and Generic Entry

Patent Term and Adjustments

The patent term for U.S. Patent 9,370,483 would typically be 20 years from the filing date of the earliest non-provisional application to which it claims priority. However, adjustments such as Patent Term Adjustments (PTA) can extend this term due to delays in the prosecution process[1].

Generic Entry

The expiration date of the patent is crucial for generic entry. Once the patent expires, generic versions of the patented product can enter the market. Websites like DrugPatentWatch provide detailed information on drug patent expirations and generic entry dates[2].

Litigation and Reexamination

Obviousness-Type Double Patenting (ODP)

ODP is a critical issue in patent law, especially for patents within the same family. The case of In re Cellect highlights the importance of ODP analysis, where claims can be invalidated if they are obvious variants of earlier patents within the same family[1].

Reexamination Proceedings

Reexamination proceedings can be initiated to challenge the validity of patent claims. The USPTO's decision in such proceedings can significantly impact the patent's validity and scope.

International Patent Landscape

Global Patent Search

To understand the global implications, it is necessary to search international patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO)[4].

Patent Family Across Jurisdictions

Using tools like the Global Dossier, one can identify related applications filed at participating IP Offices, which helps in understanding the global patent family and potential conflicts or overlaps.

Economic and Strategic Implications

Licensing and Litigation

The scope and claims of U.S. Patent 9,370,483 have significant implications for licensing and litigation. Broader claims can lead to increased licensing and litigation costs, while narrower claims may reduce these costs but also limit the patent's protective scope[3].

Innovation Incentives

The breadth and clarity of patent claims can influence innovation incentives. Overly broad or unclear claims can diminish these incentives by increasing the complexity and cost of navigating the patent landscape[3].

Key Takeaways

  • Patent Scope and Claims: The scope of U.S. Patent 9,370,483 is defined by its independent and dependent claims, with narrower claims generally associated with a higher probability of grant and shorter examination process.
  • Patent Landscape: Understanding related patents, prior art, and global patent family members is crucial for navigating the patent landscape.
  • Expiration and Generic Entry: The patent's expiration date and potential generic entry dates are vital for market planning.
  • Litigation and Reexamination: ODP analysis and reexamination proceedings can significantly impact the patent's validity.
  • International Implications: Global patent searches and understanding the patent family across jurisdictions are essential for strategic planning.

Frequently Asked Questions (FAQs)

1. What is the significance of independent claim length in patent scope?

Independent claim length is a metric used to measure patent scope. Research indicates that shorter independent claims are associated with a higher probability of grant and a shorter examination process[3].

2. How does the USPTO handle obviousness-type double patenting (ODP)?

The USPTO performs ODP analysis to ensure that claims are not obvious variants of earlier patents within the same family. This analysis can lead to the invalidation of claims if they are found to be unpatentable over earlier patents[1].

3. What tools are available for searching international patent databases?

Tools such as the Global Dossier, European Patent Office's esp@cenet, Japan Patent Office's database, and WIPO's PATENTSCOPE ® Search Service are available for searching international patent databases[4].

4. How does the breadth of patent claims affect innovation incentives?

The breadth and clarity of patent claims can significantly affect innovation incentives. Overly broad or unclear claims can increase licensing and litigation costs, thereby diminishing innovation incentives[3].

5. What is the role of the Common Citation Document (CCD) in patent searching?

The CCD consolidates prior art cited by multiple patent offices, providing a single point of access to up-to-date citation data. This helps in visualizing search results for the same invention produced by several offices on a single page[4].

Cited Sources:

  1. In re Cellect - United States Court of Appeals for the Federal Circuit.
  2. DrugPatentWatch - Detailed information on drug patent 9,370,483.
  3. SSRN - Patent Claims and Patent Scope.
  4. USPTO - Search for patents.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,370,483

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Glenmark Speclt RYALTRIS mometasone furoate; olopatadine hydrochloride SPRAY, METERED;NASAL 211746-001 Jan 13, 2022 RX Yes Yes 9,370,483 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,370,483

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3043773 ⤷  Subscribe CA 2021 00050 Denmark ⤷  Subscribe
European Patent Office 3043773 ⤷  Subscribe 301154 Netherlands ⤷  Subscribe
European Patent Office 3043773 ⤷  Subscribe 122021000085 Germany ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.